4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.250
-0.380 (-10.47%)
Mar 31, 2025, 1:43 PM EDT - Market open

4D Molecular Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2017
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2017
Revenue
0.0420.723.1318.0413.61
Upgrade
Revenue Growth (YoY)
-99.82%562.29%-82.65%32.52%94.85%
Upgrade
Cost of Revenue
141.397.180.2561.3653.04
Upgrade
Gross Profit
-141.26-76.37-77.12-43.32-39.43
Upgrade
Selling, General & Admin
46.5836.4932.9128.0117.24
Upgrade
Operating Expenses
46.5836.4932.9128.0117.24
Upgrade
Operating Income
-187.84-112.87-110.03-71.33-56.66
Upgrade
Interest & Investment Income
27.0512.212.570.140.15
Upgrade
Other Non Operating Income (Expenses)
-0.08-0.18-0.04-0.12-0.18
Upgrade
EBT Excluding Unusual Items
-160.87-100.84-107.49-71.32-56.69
Upgrade
Pretax Income
-160.87-100.84-107.49-71.32-56.69
Upgrade
Net Income
-160.87-100.84-107.49-71.32-56.69
Upgrade
Net Income to Common
-160.87-100.84-107.49-71.32-56.69
Upgrade
Shares Outstanding (Basic)
543932286
Upgrade
Shares Outstanding (Diluted)
543932286
Upgrade
Shares Change (YoY)
37.86%20.95%16.66%331.23%25.05%
Upgrade
EPS (Basic)
-2.98-2.58-3.32-2.57-8.82
Upgrade
EPS (Diluted)
-2.98-2.58-3.32-2.57-8.82
Upgrade
Free Cash Flow
-138.37-78.56-98.22-78.24-51.91
Upgrade
Free Cash Flow Per Share
-2.56-2.01-3.04-2.82-8.07
Upgrade
Gross Margin
----240.17%-289.64%
Upgrade
Operating Margin
-507678.38%-544.65%-3516.52%-395.46%-416.28%
Upgrade
Profit Margin
-434778.38%-486.59%-3435.41%-395.37%-416.49%
Upgrade
Free Cash Flow Margin
-373975.68%-379.11%-3139.05%-433.77%-381.35%
Upgrade
EBITDA
-183.19-108.66-107.63-69.81-55.22
Upgrade
D&A For EBITDA
4.654.22.41.521.44
Upgrade
EBIT
-187.84-112.87-110.03-71.33-56.66
Upgrade
Revenue as Reported
----13.61
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q